

A decorative horizontal bar with a blue segment on the left and a yellow segment on the right.

## News Release

18 May 2018

### **SGX welcomes Hyphens Pharma International Limited to Catalist**

Singapore Exchange (SGX) today welcomed Hyphens Pharma International Limited to its Catalist under the stock code "1J5".

Hyphens Pharma International Limited is one of Singapore's leading specialty pharmaceutical and consumer healthcare groups with a diverse footprint in ASEAN countries.

The Group is in the business of selling and marketing of specialty pharmaceutical products for brand principals mainly from Europe and the United States; developing, marketing and selling its own proprietary range of dermatological products and health supplement products through Hyphens and Ocean Health Singapore; and wholesaling pharmaceuticals and medical supplies in Singapore through Pan-Malayan, a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.

Lim See Wah, Chairman, Executive Director and CEO, Hyphens Pharma International Limited, said, "We are encouraged by the strong response for our IPO, which is a clear signal of investors' confidence in the Group's strong track record and network, our portfolio of internationally well-known specialty pharmaceutical products as well as proprietary range of products and brands. With the success of our IPO, we are well-placed to expand and strengthen our product range and maintain growth momentum through scaling our presence in markets that we operate in and expanding into new geographical markets. We are delighted to have our stakeholders participate alongside our growth story."

Mohamed Nasser Ismail, Head of Equity Capital Market (SME) and Head of Capital Market Development at SGX, said, "We are delighted to welcome Hyphens Pharma International Limited to Catalist, an established player in the specialty pharmaceutical and consumer healthcare space in Singapore, with a brand heritage of more than 70 years. This is a timely listing as the Group looks set to deepen its presence in existing markets and further internationalise its business, at a time when demand for high quality wellness products continues to increase. Through this listing, investors will also have an opportunity to partake in the growing healthcare industry."

With a market capitalisation of S\$78 million, the listing of Hyphens Pharma International Limited brings the total number of healthcare companies listed on SGX to 38, with a combined market capitalisation of more than S\$63 billion. The total number of companies listed on [Catalist](#) rises to 205, with a combined market capitalisation of over S\$12 billion.

Hyphens Pharma International Limited opened at S\$0.30 today.

-End-

## About Hyphens Pharma International Limited

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapore's leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.

The Group's core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

## About Singapore Exchange (SGX)

Singapore Exchange is Asia's leading and trusted market infrastructure, operating equity, fixed income and derivatives markets to the highest regulatory standards. As Asia's most international, multi-asset exchange, SGX provides listing, trading, clearing, settlement, depository and data services, with about 40% of listed companies and 75% of listed bonds originating outside of Singapore.

SGX is the world's most liquid offshore market for the benchmark equity indices of China, India, Japan and ASEAN and offers commodities and currency derivatives products. Headquartered in AAA-rated Singapore, SGX is globally recognised for its risk management and clearing capabilities. For more information, please visit [www.sgx.com](http://www.sgx.com).

## Media Contacts

Ho Lily  
Marketing & Communications  
+65 6713 6786  
[lily.ho@sgx.com](mailto:lily.ho@sgx.com)

**Singapore Exchange Limited**  
Company Reg No. 199904940D

2 Shenton Way, #02-02 SGX Centre 1, Singapore 068804  
main: +65 6236 8888 fax: +65 6535 6994  
[sgx.com](http://sgx.com)